Bristol Myers Squibb's Opdivo plus AVD wins EU approval for frontline advanced Hodgkin lymphoma

Bristol-Myers Squibb

Bristol-Myers Squibb

BMY

0.00
  • European Commission cleared Bristol Myers Squibb’s Opdivo with AVD for first-line Stage III-IV classical Hodgkin lymphoma in patients aged 12 and older.
  • Decision sets the EU’s first immunotherapy-based regimen for newly diagnosed advanced cHL.
  • Approval relied on Phase 3 SWOG 1826 data showing a 58% lower risk of progression or death vs brentuximab vedotin with AVD (HR 0.42).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260531664389) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.